InvestorsHub Logo
Followers 21
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Thursday, 07/23/2020 1:31:06 PM

Thursday, July 23, 2020 1:31:06 PM

Post# of 209
Jul 23, 2020 9:17 AM
ARAV Aravive price target raised to $26 from $15 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm's price target on Aravive to $26 from $15 and keeps a Buy rating on the shares after the company announced the completion of its Phase 1b trial testing AVB-500 in patients with platinum-resistant ovarian cancer. As expected, these data confirmed prior observations of safety and efficacy and provided key information for the design of the upcoming Phase 2/3 trial, Pantginis tells investors in a research note.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARAV News